Evan Wang
Stock Analyst at Guggenheim
(n/a)
# 4,715
Out of 4,944 analysts
5
Total ratings
n/a
Success rate
-47.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Maintains: Buy | $56 → $62 | $30.87 | +100.84% | 1 | Jun 10, 2025 | |
| CVAC CureVac | Reiterates: Neutral | n/a | $5.50 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $0.79 | +1,034.93% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $11.16 | +52.33% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $26.89 | - | 1 | Apr 26, 2023 |
Metsera
Jun 10, 2025
Maintains: Buy
Price Target: $56 → $62
Current: $30.87
Upside: +100.84%
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $5.50
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $0.79
Upside: +1,034.93%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $11.16
Upside: +52.33%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $26.89
Upside: -